Mehrotra et al. used these three peptide-loaded DCs in conjunction with TLR-3 agonist poly-ICLC to treat PC patients with metastatic or locally advanced unresectable PC in a clinical study (58). Here, TLR3 is linked to pachyonychia congenita.